Status: Recruiting
A Phase 3 Trial of DT120 for Major Depressive Disorder (Ascend)
A Phase 3 Double-blind, Placebo-controlled Study (Part A) with an Open-label Extension (Part B) Evaluating DT120 Compared to Placebo in Major Depressive Disorder - Ascend
Participants needed: 165
Trial details
Phase: Phase 3Age: 18-74Biological sex: AllType: InterventionalSponsor: Definium Therapeutics US, Inc.Updated: Jun 29, 2026Locations: 27
Eligibility criteria
Diagnosis of MDD per DSM-5 [+4]
Certain psychiatric disorders (other than major depressive disorder) [+3]